Life Biosciences, a Boston longevity biotech co-founded by Harvard genetics professor David Sinclair, has locked down an $80 ...

Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

A startup cofounded by a renowned Harvard geneticist has taken a step toward cracking the human body’s biological breakdown by securing FDA approval to test its cutting-edge gene therapy on humans.

For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

ER-300 improves key biomarkers of liver health in an animal model of MASH These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear ...

In the cancer type multiple myeloma, the malignant cells differ significantly from normal cells regarding the layer of chemical “tags” on DNA and proteins that control whether genes are turned on or ...

According to a team of researchers at Baylor College of Medicine, Tongji University and collaborating institutions, weaning or switching from milk to solid food in early life doesn't just change what ...

Before a child speaks a first word or misses a developmental milestone, clues about autism and ADHD risk may already be ...